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The development and dissemination of left ventricular assist
devices (LVADs) for the treatment of end-stage heart failure
have been one of the major developments in heart failure
over the past decade, and the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS)
database, funded by the National Heart, Lung, and Blood
Institute, has been a critical resource for tracking practice
patterns, outcomes, and post-operative complications (1). In
this issue of the Journal, the report by Oliveira et al. (2) on
outcomes in patients with a history of anthracycline-induced
cardiomyopathy after mechanical circulatory support (MCS)
from the INTERMACS registry is an example of work that
would be impossible to perform from single-center data,
as highlighted by the fact that only 2% of 3,812 eligi-
ble MCS-implanted patients were reported to have
anthracycline-based cardiomyopathy.
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As the number of cancer survivors grows, we can expect to
see more patients affected by the late consequences of car-
diotoxic medications such as anthracyclines (3). This can be
quite a roller coaster for patients who have survived cancer
only to ﬁnd that they now are at risk of major morbidity and
mortality from a diagnosis of heart failure! Although newer
agents such as trastuzumab and tyrosine kinase inhibitors are
well established as a potential cause of heart failure, anthra-
cyclines remain the dominant agent. Despite their use for
decades as a cornerstone of the treatment of breast cancer,
hematological malignancies, and sarcomas, the mechanism
of anthracycline cardiotoxicity remains incompletely under-
stood. Generation of reactive oxygen species has been the
dominant theory, but other mechanisms are likely to be
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Thoratec.has been demonstrated to induce protein ubiquination and
inhibit proteasome activity (5); proteasome inhibition has
previously been reported to cause heart failure (6).
Anthracyclines block topoisomerase II (TOP2), a critical
enzyme involved in DNA replication. Genetically engi-
neered mice have recently been developed that do not
express the isomer TOP2B and appear to avoid acute or
chronic cardiotoxicity from exposure to doxorubicin (7),
implying a promising option. An anthracycline with speci-
ﬁcity for TOP2A, a marker of cell proliferation and thus
overexpressed in malignant cells, may offer substantial
reductions in cardiotoxicity without compromising anti-
neoplastic effect, a concern that has been raised with dex-
razoxane (8).
Along with our improved, but incomplete, understanding
of the mechanism of anthracycline cardiotoxicity, it is
obvious in retrospect that much less attention has been paid
to the impact on the right ventricle. Most studies have re-
ported on the effect on left ventricular (LV) ejection fraction,
which is often the dominant, if not sole, parameter used to
monitor for myocardial toxicity in clinical practice, although
biomarkers appear to improve sensitivity and timeliness of
diagnosis (9). A welcome addition to the literature was
a recent study from Finland that reported on LV and right
ventricular (RV) cardiac structure and function in a series of
long-term survivors of childhood cancer using cardiac
magnetic resonance imaging. Although this population may
not be representative of the larger population receiving
anthracyclines, such as older lymphoma and breast cancer
patients, it is notable thatw80% of participants had frankly
abnormal or subnormal LV and RV ejection fractions, and
RV end-diastolic volume was also increased compared with
a reference population (10).
The right ventricle is of great interest to clinicians
involved in the care of patients being considered for MCS
with an LVAD, as post-LVAD RV failure has a poor
prognosis. Our understanding of patient selection and per-
ioperative management of RV function has led to a signiﬁ-
cant decrease in the number of post-LVAD patients in
whom RV failure develops, typically deﬁned as the need for
inhaled nitric oxide, administration inotrope beyond 14
days, or implantation of an RV assist device. In contrast to
earlier reports, contemporary estimates of RV failure
requiring an RV assist device after LVAD are typically in the
range of 5% or less (11). However, predicting RV failure
remains challenging, and the number of published predic-
tion tools is de facto evidence that we do not yet have
a simple answer to the question, “Will this patient’s RV
function be sufﬁcient to support an LVAD or is another
mode of MCS required?”
Oliveira et al. (2) identiﬁed 75 patients from the
INTERMACS registry who underwent LVAD implanta-
tion with a history of chemotherapy-induced cardiomyopathy
(CCMP) and compared them with others with ischemic
cardiomyopathy (ICMP) and nonischemic cardiomyopathy
(NICMP [other than chemotherapy induced]). They noted
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250that the CCMP group had fewer comorbidities such as dia-
betes, history of alcohol abuse, and current smoking and was
highly enriched with female patients (72% vs. 13% and 24%
for ICMP and NICP, respectively). INTERMACS proﬁles,
a shorthand tool to stratify acuity in patients receiving MCS,
were well matched between the 3 groups. It is not surprising
that the CCMP group had far more women than previous
studies of LVADs, as anthracyclines are a key element of
most breast cancer treatment regimens, a disease this is
distinctly less common in men. Survival after LVAD was
equivalent in the CCMP group, but the risk of postoperative
RV failure doubled to w20%. This ﬁnding is important
because, on the basis of this study, it may be prudent to add
a history of anthracycline exposure as a risk factor for RV
failure after LVAD implantation. Pre-implantation hemo-
dynamics, characterized by increased central venous pressure
and lower pulmonary artery pressures in the CCMP group,
may have provided a clue to the increased risk of RV failure,
and particular concern over such marginal hemodynamics in
this group is warranted.
The observation that the risk of RV failure after LVAD
implantation is higher in patients with anthracycline car-
diotoxicity is concordant with what might be expected, given
contemporary understanding of the mechanism of anthra-
cycline toxicity and recent evidence highlighting the likeli-
hood of biventricular impairment. One of the important
results of the Oliveira et al. (2) study is that it provides ad-
ditional support of the observation that biventricular
failure might be expected after anthracyclines and that it
strengthens the case to consider a cardiac monitoring strategy
during administration of potentially cardiotoxic chemo-
therapy that explicitly includes the right ventricle.
Some important caveats bear mention, including the
inherent limitations of registry data, as noted by the authors
(11% did not have a history of cancer listed with INTER-
MACS, and 8% of the NICMP patients had a history of
coronary artery bypass grafting, for example). We are also
left without information on patients with a history of
cardiomyopathy due to other chemotherapy agents that have
been implicated in the pathogenesis of heart failure, such as
trastuzumab and tyrosine kinase inhibitors.
It is remarkable that only 1 CCMP patient is described as
dying of cancer after LVAD implantation, suggesting that
the underlying malignancy was thought to be in remission
with some conﬁdence in most patients before implantation.
As the authors indicate, “because of the stigma associated
with the etiology of their heart failure, they may be subjected
to stricter requirements for MCS eligibility than their ICMP
and NICMP counterparts,” which is corroborated by the
lower incidence of alcohol abuse history and increased
frequency of implantation intent of destination therapy inthe CCMP group. Accordingly, some caution is needed
before extrapolating the present data to everyone with
a history of CCMP, as the study population had fewer other
comorbidities and was likely to have been enriched with
patients with lower risk of cancer recurrence. Nevertheless,
the key message is one of validation that CCMP patients
with end-stage heart failure are likely to have outcomes
after LVAD implantation comparable to those without
anthracycline-induced cardiomyopathy and should not be
excluded from the possibility of beneﬁt solely on the basis of
this history.
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